Palisade Bio raises $3.0M in stock sale

Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc. d/b/a Iterative Health to help enroll patients in its planned Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis.

Rhea-AI Filing Summary

Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc. d/b/a Iterative Health to help enroll patients in its planned Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis. To support this collaboration, the company issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health for a total of $3.0 million, at $1.952 per share, which matches the average closing price over the five trading days before the closing date. The shares were sold in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

Insights

Biotech capital markets analyst

Palisade Bio combines strategic trial support with a $3.0M equity raise.

Palisade Bio is funding and operationally supporting its planned Phase 2 ulcerative colitis study by pairing a master services agreement with Iterative Health and a targeted equity sale. The affiliate investor purchased 1,536,885 common shares for $3.0 million at $1.952 per share, aligned with the recent five-day average closing price.

This structure brings in cash while tying a specialist partner directly to the program through equity ownership. The impact will depend on how effectively Iterative Health accelerates patient enrollment for the Phase 2 PALI-2108 trial. Forward-looking language underscores typical clinical and operational risks referenced in the company’s Form 10-K.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Equity proceeds: $3.0 million Shares issued: 1,536,885 shares Share price: $1.952 per share +2 more

5 metrics

Equity proceeds $3.0 million Total purchase price for common stock issued to Investor

Shares issued 1,536,885 shares Common stock sold to an affiliate of Iterative Health

Share price $1.952 per share Sale price, equal to 5-day average closing price before closing

Phase Phase 2 Planned clinical study stage for PALI-2108 in ulcerative colitis

Registration exemption Section 4(a)(2) Exemption under Securities Act of 1933 used for the share sale

Key Terms

master services agreement, Phase 2 study, ulcerative colitis, Section 4(a)(2), +1 more

5 terms

master services agreement financial

"entered into a master services agreement (the “MSA”) with Iterative Scopes, Inc."

A master services agreement is a standing contract that sets the main terms, responsibilities, pricing framework and processes for future work between two parties, allowing individual projects or orders to be added later without renegotiating core terms. For investors, it signals predictability and reduced legal friction around revenue streams and costs—like a subscription plan for services that makes future income and obligations easier to forecast and value.

Phase 2 study technical

"In preparation for the expected Phase 2 study of PALI-2108 for the treatment"

A phase 2 study is a mid-stage clinical trial that tests whether an experimental drug or treatment actually works for the intended condition and continues to check safety in a larger group of patients than early trials. Think of it as a focused pilot test before a full market launch; positive or negative results strongly affect a drug’s chances of approval, the remaining development time and costs, and therefore an investment’s risk and potential value.

ulcerative colitis medical

"for the treatment of patients with moderate to severe Ulcerative Colitis (“UC”)"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

Section 4(a)(2) regulatory

"in reliance on Section 4(a)(2) thereof."

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

forward-looking statements regulatory

"This on contains “forward-looking” statements for purposes of the safe harbor"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did Palisade Bio (PALI) sign with Iterative Health?

Palisade Bio signed a master services agreement with Iterative Scopes, Inc. d/b/a Iterative Health. The agreement covers assistance with patient enrollment for the company’s planned Phase 2 study of PALI-2108 in moderate to severe ulcerative colitis.

How much capital did Palisade Bio (PALI) raise in this transaction?

Palisade Bio raised $3.0 million by issuing common stock to an affiliate of Iterative Health. This funding is tied to their collaboration around the planned Phase 2 ulcerative colitis study and was completed through a private placement.

How many Palisade Bio (PALI) shares were issued and at what price?

The company issued 1,536,885 shares of common stock at $1.952 per share. The price reflects the average closing price of Palisade Bio’s stock on the Nasdaq Capital Market over the five trading days before the closing date.

Was the Palisade Bio (PALI) share sale registered with the SEC?

No, the share sale was conducted as a private transaction exempt from registration. Palisade Bio relied on Section 4(a)(2) of the Securities Act of 1933, which allows certain non-public offerings without SEC registration.

What is the purpose of the Phase 2 PALI-2108 study for Palisade Bio (PALI)?

The planned Phase 2 study of PALI-2108 targets patients with moderate to severe ulcerative colitis. Palisade Bio aims to evaluate the treatment in this population and is partnering with Iterative Health to help expedite patient enrollment into the trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 08:34 AM EDT Learn about SEC filing dates

false 0001357459 0001357459 2026-03-27 2026-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2026

PALISADE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-33672		52-2007292
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4600 South Syracuse Street Suite 900
Denver, Colorado		80237
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 704-4900

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		PALI		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

In preparation for the expected Phase 2 study of PALI-2108 for the treatment of patients with moderate to severe Ulcerative Colitis (“UC”), and in order to expedite the enrollment of patients (the “Study Enrollment”), on March 30, 2026, Palisade Bio, Inc. (the “Company”) entered into a master services agreement (the “MSA”) with Iterative Scopes, Inc. d/b/a Iterative Health (“IH”), pursuant to which IH has agreed to, among other things, assist the Company with the Study Enrollment.

On March 27, 2026 (the “Closing Date”), the Company issued and sold 1,536,885 shares (the “Shares”) of common stock, par value $0.01 per share (“Common Stock”), of the Company to an affiliate of IH (the “Investor”) for a total purchase price of $3.0 million, or $1.952 per Share (which represents the average closing price of the Common Stock on the Nasdaq Capital Market for the five trading days prior to the Closing Date), pursuant to a common stock purchase agreement, dated March 27, 2026, by and between the Company and the Investor. The Shares were offered and sold in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) thereof.

Forward Looking Statements

This Current Report on Form 8-K contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s plans for its Phase 2 clinical study in UC and the enrollment of patients. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the risks and uncertainties outlined in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 20, 2026. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 2, 2026	Palisade Bio, Inc.
		/s/ J.D. Finley
	By:	J.D. Finley
		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB